Epigenetic Dysregulation in Cancer
Authors:
- Jay L. HessJHJay L. Hess
- 1 October 2009
- journal article
- Published by Elsevier in The American Journal of Pathology
- Vol. 175 (4) , 1353-1361
Abstract
No abstract availableKeywords
This publication has 99 references indexed in Scilit:
- The Polycomb group gene Ezh2 prevents hematopoietic stem cell exhaustionBlood, 2006
- EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and BreastJournal of Clinical Oncology, 2006
- Comprehensive genomic analysis of desmoplastic medulloblastomas: identification of novel amplified genes and separate evaluation of the different histological componentsThe Journal of Pathology, 2006
- ING Tumor Suppressor Proteins Are Critical Regulators of Chromatin Acetylation Required for Genome Expression and PerpetuationMolecular Cell, 2006
- Epigenetic therapy of cancer: past, present and futureNature Reviews Drug Discovery, 2006
- Leukemogenic MLL Fusion Proteins Bind across a Broad Region of the Hox a9 Locus, Promoting Transcription and Multiple Histone ModificationsCancer Research, 2005
- The Polycomb group protein EZH2 directly controls DNA methylationNature, 2005
- The fellowships of the INGsJournal of Cellular Biochemistry, 2005
- The polycomb group protein enhancer of zeste homolog 2 (EZH2) is an oncogene that influences myeloma cell growth and the mutant ras phenotypeOncogene, 2005
- The SET-domain protein superfamily: protein lysine methyltransferasesGenome Biology, 2005